NeurologyLive® Friday 5 — December 5, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD

At CTAD 2025, the senior vice president of medical and scientific relations at the Alzheimer's Association talked about how structured lifestyle interventions improved blood pressure and sleep in the U.S. POINTER study. [WATCH TIME: 4 minutes]

2: Screening At-Risk Patients to Accelerate SMA Diagnosis and Treatment: Karlla W. Brigatti, MS, CGC

At NSGC 2025, the research director at the Clinic for Special Children discussed the clinic’s approach to accelerating the diagnosis and treatment of spinal muscular atrophy. [WATCH TIME: 5 minutes]

3: Expanding Neurology Care in South Miami: Peter Abdelmalik’s Vision

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

4: NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

5: Exploring Complement Inhibition and Claseprubart in CIDP

Panelist discuss complement inhibition as an emerging, mechanism-specific approach to managing chronic inflammatory demyelinating polyneuropathy (CIDP) and describe ongoing research evaluating its clinical potential.